Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
72.1M
-
Number of holders
-
80
-
Total 13F shares, excl. options
-
47.6M
-
Shares change
-
+1.22M
-
Total reported value, excl. options
-
$44.4M
-
Value change
-
+$934K
-
Put/Call ratio
-
0.08
-
Number of buys
-
35
-
Number of sells
-
-27
-
Price
-
$0.93
Significant Holders of Ovid Therapeutics Inc. - Common Stock, par value $0.001 per share (OVID) as of Q4 2024
90 filings reported holding OVID - Ovid Therapeutics Inc. - Common Stock, par value $0.001 per share as of Q4 2024.
Ovid Therapeutics Inc. - Common Stock, par value $0.001 per share (OVID) has 80 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 47.6M shares
of 72.1M outstanding shares and own 66.01% of the company stock.
Largest 10 shareholders include TAKEDA PHARMACEUTICAL CO LTD (7.53M shares), Rubric Capital Management LP (5.32M shares), BlackRock, Inc. (3.93M shares), BVF INC/IL (3.85M shares), Madison Avenue Partners, LP (3.72M shares), VANGUARD GROUP INC (3.15M shares), Siren, L.L.C. (2.85M shares), ACADIAN ASSET MANAGEMENT LLC (1.85M shares), KENNEDY CAPITAL MANAGEMENT LLC (1.55M shares), and JPMORGAN CHASE & CO (1.42M shares).
This table shows the top 80 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.